Aaron Kantoff
Co-Founder & Managing Partner at Scion Life Sciences
New York, New York
Overview
Work Experience
Co-Founder & Managing Partner
2022 - Current
Board Member
2024
Leading research foundation for the diagnosis and treatment of Pancreatic Cancer
Board Member
2022
Developing transformative medicines that dramatically improve the lives of patients with immune & inflammatory diseases. Lead program, TOUR001, is an anti-IL6L for treatment of autoantibody mediated diseases and inflammatory cardiovascular disorders. NASDAQ: TRML
Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.
Raised $359,500,000.00 from Cowen Healthcare Investments, Deep Track Capital, Affinity Asset Advisors, Braidwell, StemPoint Capital, Logos Capital, Paradigm BioCapital Advisors, Acuta Capital Partners, TCG Crossover and Qiming Venture Partners USA.
Founding Board Member
2020 - 2024
Targeted Radiotherapy. Acquired by Bristol Myers Squibb for $4.1B.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Raised $418,000,000.00 from Soleus Capital, Ally Bridge Group, Viking Global Investors, Laurion Capital Management, Wellington Management, Sands Capital Ventures and Sofinnova Investments.
Board Member
2020 - 2022
NASDAQ: CNTA
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.
Raised $875,000,000.00 from Oberland Capital.
Venture Partner
2020 - 2021
Board Member
2018 - 2019
Leading metabolic disease company. Developing a long-acting Fc Fusion modified fibroblast growth factor 21 (FGF21), AKR-001, for NASH and other metabolic diseases. NASDAQ: AKRO
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Raised $951,100,000.00 from Hercules Capital.
Board Member
2016 - 2019
Developing precision medicines for cardiovascular disease Acquired by Novo Nordisk for $2.1B in total cash considerations
Board Member
2015 - 2019
Elstar Therapeutics is leveraging recent technological advances in antibody engineering to generate best-in-class multi-specific and multi-functional immunotherapies. These molecules harness our growing understanding of immune modulation to treat a variety of hematological malignancies and solid tumors.
Partner
2011 - 2019
Apple Tree Partners (ATP), is a venture capital firm that invests in and builds biotech companies.
Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Raised $5,000,000.00.